EMERYVILLE, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Neurobiological
Technologies, Inc. (Nasdaq: NTII), today announced that Paul E. Freiman,
President and Chief Executive Officer, will present at the Seventh Annual
BIO Investor Forum on October 29 and 30, 2008 at The Palace Hotel in San
Francisco. Mr. Freiman's presentation will take place at 11 a.m. (Pacific
time) on October 30.
The presentation will be webcast and can be accessed by going to:
About Neurobiological Technologies, Inc.
Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases, rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.
|SOURCE Neurobiological Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved